March 11, 2020
Visceral Fat Is A Predictor Of Liver Fibrosis And Fibrosis Progression In People Living With HIV
Montreal, Canada – March 11, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that Dr. Lindsay Fourman, from Harvard Medical School, presented data demonstrating that visceral fat is a clinical predictor of liver fibrosis and liver fibrosis progression in an oral presentation during CROI 2020. These findings highlight the critical role played by excess visceral adiposity in the progression of fibrosis among HIV-infected patients with nonalcoholic fatty liver disease. This information may further inform the field as to the development of prediction tools and therapeutic strategies for hepatic fibrosis in this population.
This finding comes from a sub-analysis of the recent study led by Dr. Steven Grinspoon and conducted at the Massachusetts General Hospital and the National Institute of Allergy and Infectious Diseases and funded by the NIH, to assess the effect of tesamorelin on NAFLD/NASH in patients living with HIV. The study was published in the October 2019 issue of The Lancet HIV Journal.